MyDosage · Personal evidence dossier
Sexual health
Melanocortin and kisspeptin pathways for libido and arousal.
DSR-SEXU-20260820
Issued August 20, 2026
Editorial · independent
01Top candidate
PT-141
α-MSH analogue (MC4) · t½ ~2.7 h
Cyclic α-MSH analogue approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women.
Evidence Intelligence Score™
6.3/ 10Moderate
Strongest
Effects on the indexed outcomes are supported by randomized human data, with 1 citation on file.
Weakest
Effect sizes outside trial populations and durations beyond the studied window remain less characterized.
Unknowns
Interactions outside listed contraindications, long-term safety, and effect heterogeneity across age and sex are not fully resolved.
Outlook
Outlook: maturing. Expect the consensus to harden as multi-site replications publish.
02Ranked candidates
- 01PT-141α-MSH analogue (MC4)6.3A
- 02Melanotan IIα-MSH analogue (cyclic)3.6C
03Safety register
- PT-141Uncontrolled hypertension · Cardiovascular disease
- Melanotan IIPregnancy · Personal/family melanoma · History of moles/dysplastic nevi